Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression,including in patients with PD-L1 CPS<5.
RIYADH,Saudi Arabia,May 24,2024-- Recently in Riyadh,Newrizon,a startup dedicated in electrifying and revolutionizing urban delivery vehicles,signed dealership agreement and intent purchase order with
BANGKOK,May 24,2024-- NEC Corporation (Thailand) Limited (NEC Thailand) has announced a strategic partnership with AIRA Factoring Public Company Limited (AIRA Factoring) to elevate digital supply cha
HONG KONG,May 24,2024-- New Frontier Group (hereinafter referred to as "New Frontier") announces today that it has completed the acquisition of Hong Kong Integrated Oncology Centre (hereinaf
SHANGHAI,May 24,2024-- Xiao-I Corporation (NASDAQ: AIXI) ("Xiao-I" or the "Company"),a leading AI company announces an important partnership with a major Chinese banking institutio
SHANGHAI,May 24,2024-- Shanghai Juncell Therapeutics Co.,Ltd. (Juncell Therapeutics),a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers,announced
